Skip to main content
Addgene

pLenti-EML4-ALK variant 3a I1171N
(Plasmid #183832)

Print

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 183832 Standard format: Plasmid sent in bacteria as agar stab 1 $85
Add to Cart

Backbone

  • Vector backbone
    pLenti
  • Backbone size w/o insert (bp) 7877
  • Total vector size (bp) 10235
  • Vector type
    Mammalian Expression, Lentiviral
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    Unknown

Gene/Insert 1

  • Gene/Insert name
    ALK Receptor Tyrosine Kinase
  • Alt name
    ALK
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    1691
  • Mutation
    I1171N
  • GenBank ID
    NM_004304
  • Entrez Gene
    ALK (a.k.a. ALK1, CD246, NBLST3)
  • Promoter CMV
  • Tag / Fusion Protein
    • The fusion protein of EML4 exon 1-6a and ALK exon 20-29

Cloning Information for Gene/Insert 1

Gene/Insert 2

  • Gene/Insert name
    EMAP Like 4
  • Alt name
    EML4
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    667
  • GenBank ID
    NM_019063.5
  • Entrez Gene
    EML4 (a.k.a. C2orf2, ELP120, EMAP-4, EMAPL4, ROPP120)
  • Promoter CMV
  • Tag / Fusion Protein
    • The fusion protein of EML4 exon 1-6a and ALK exon 20-29

Cloning Information for Gene/Insert 2

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLenti-EML4-ALK variant 3a I1171N was a gift from Aaron Hata (Addgene plasmid # 183832 ; http://n2t.net/addgene:183832 ; RRID:Addgene_183832)

  • For your References section:

    Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Shiba-Ishii A, Johnson TW, Dagogo-Jack I, Mino-Kenudson M, Johnson TR, Wei P, Weinrich SL, McTigue MA, Walcott MA, Nguyen-Phuong L, Dionne K, Acker A, Kiedrowski LA, Do A, Peterson JL, Barth JL, Yeap BY, Gainor JF, Lin JJ, Yoda S, Hata AN. Nat Cancer. 2022 Jun 20. pii: 10.1038/s43018-022-00399-6. doi: 10.1038/s43018-022-00399-6. 10.1038/s43018-022-00399-6 PubMed 35726063
Related items:
Commonly requested with: